Andrographolide

Alternative Names: 3α,14,15,18-tetrahydroxy-5β,9βH,10α-labda-8(20),12-dien-16-oic acid γ-lactone, AP extract, Kalmegh extract, King of Bitters extract, Chuan Xin Lian active compound

Categories: Diterpenoid lactone, Phytochemical, Labdane diterpene

Primary Longevity Benefits

---

Secondary Benefits

---

Mechanism of Action

---

Optimal Dosage

---

The optimal dosage of andrographolide varies based on the specific health condition being addressed, the form of supplementation, individual factors, and the concentration of active compounds in the preparation. For standardized Andrographis paniculata extracts containing 4-30% andrographolide, clinical studies have established several evidence-based dosage ranges. For acute upper respiratory tract infections, including common cold and influenza, clinical trials have shown efficacy with 400-1200 mg of standardized extract (providing approximately 4-36 mg of andrographolide) daily, divided into 2-3 doses for 3-5 days. For this application, higher doses within this range are typically used at the onset of symptoms, with gradual reduction as symptoms improve.

For chronic inflammatory conditions such as rheumatoid arthritis and ulcerative colitis, clinical studies have utilized 800-1600 mg of standardized extract (providing approximately 30-60 mg of andrographolide) daily for 8-12 weeks. This dosage is typically divided into 2-3 administrations throughout the day to maintain steady blood levels. For metabolic conditions including type 2 diabetes and non-alcoholic fatty liver disease, research suggests 600-1200 mg of standardized extract (providing approximately 20-40 mg of andrographolide) daily for 8-12 weeks shows beneficial effects on glycemic control and liver function parameters. For general immune support and preventive use, lower doses of 200-400 mg of standardized extract (providing approximately 6-12 mg of andrographolide) daily are commonly recommended.

When using isolated andrographolide (95-98% purity) rather than whole plant extracts, the dosage is substantially lower, typically ranging from 5-30 mg daily, as the compound is more concentrated. However, isolated andrographolide may lack the synergistic benefits of other compounds present in the whole plant extract. The timing of administration can significantly impact efficacy. For acute conditions, more frequent dosing (3-4 times daily) helps maintain therapeutic blood levels.

For chronic conditions, twice-daily dosing with meals is typically recommended to enhance absorption and minimize potential gastrointestinal effects. Special populations require dosage adjustments. For children (when appropriate and under medical supervision), doses are typically calculated at 50-75% of the adult dose based on body weight. For elderly individuals or those with compromised liver or kidney function, starting at the lower end of the dosage range (approximately 200-400 mg of extract daily) is recommended with gradual titration based on response and tolerance.

For pregnant or lactating women, andrographolide is generally not recommended due to insufficient safety data. The duration of use varies by condition. For acute infections, short-term use of 3-10 days is typical. For chronic conditions, cycles of 8-12 weeks of supplementation followed by a 2-4 week break are often recommended to prevent tolerance and assess ongoing need.

It’s important to note that andrographolide has a relatively short half-life (approximately 2-3 hours), which necessitates multiple daily doses for sustained effects. Enhanced delivery systems such as liposomal formulations may allow for less frequent dosing due to improved bioavailability and extended release profiles. Clinical research indicates that the therapeutic window of andrographolide is relatively narrow, with efficacy diminishing at both too low and too high doses. This biphasic dose-response relationship has been particularly noted in immunomodulatory and anti-inflammatory applications, where excessive doses may paradoxically reduce effectiveness.

Due to potential herb-drug interactions and individual variability in response, dosage should be personalized under professional guidance, particularly for individuals taking medications or with pre-existing health conditions.

Bioavailability

---

Safety Profile

---

Regulatory Status

---

The regulatory status of andrographolide varies significantly across different regions and jurisdictions, reflecting diverse approaches to the regulation of botanical compounds and their derivatives. In the United States, andrographolide is regulated by the Food and Drug Administration (FDA) as a dietary supplement ingredient under the Dietary Supplement Health and Education Act (DSHEA) of 1994. As a dietary supplement component, products containing andrographolide cannot claim to diagnose, treat, cure, or prevent any disease, but can make structure/function claims (e.g., ‘supports immune health’) if the manufacturer has substantiation for such claims. The FDA does not review dietary supplements for safety and efficacy before they reach the market, placing the responsibility on manufacturers to ensure their products are safe and properly labeled.

Andrographolide has not been approved as a drug by the FDA, though it has been the subject of several Investigational New Drug (IND) applications for specific therapeutic indications. In the European Union, the regulatory landscape for andrographolide is more complex. The European Medicines Agency (EMA) has assessed Andrographis paniculata through its Committee on Herbal Medicinal Products (HMPC), which published a community herbal monograph in 2014. This monograph acknowledges the traditional use of Andrographis for the common cold based on long-standing use but notes insufficient evidence for ‘well-established use’ status, which would require more substantial clinical evidence.

In some EU member states, including Sweden, Germany, and Austria, Andrographis products standardized for andrographolide content are registered as traditional herbal medicinal products under the Traditional Herbal Medicinal Products Directive (THMPD). These products can make specific health claims related to their traditional use for upper respiratory tract infections and fever. In other EU countries, andrographolide products may be sold as food supplements, subject to general food safety regulations and the Nutrition and Health Claims Regulation, which strictly limits the health claims that can be made. In China, Andrographis paniculata (Chuan Xin Lian) is included in the Chinese Pharmacopoeia and is regulated as a traditional Chinese medicine by the National Medical Products Administration.

The pharmacopoeia establishes quality standards, including minimum andrographolide content requirements. Andrographolide and its derivatives are also being developed as modern pharmaceuticals in China, with several candidates in clinical trials for various indications. In India, Andrographis paniculata (Kalmegh) is recognized in the Ayurvedic Pharmacopoeia of India and regulated as a traditional Ayurvedic medicine by the Ministry of AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homeopathy). Products following traditional formulations can be marketed with minimal additional regulatory requirements, while innovative formulations require more extensive documentation.

The Indian Pharmacopoeia Commission has established quality standards for Andrographis, including specifications for andrographolide content. In Thailand, Andrographis paniculata (Fah Talai Jone) has received significant regulatory attention, particularly during the COVID-19 pandemic. In 2020, the Thai Food and Drug Administration approved Andrographis extracts standardized for andrographolide content for treatment of mild COVID-19 cases, representing one of the most progressive regulatory approaches to this botanical worldwide. Andrographis is included in Thailand’s National List of Essential Medicines for upper respiratory infections.

In Australia, the Therapeutic Goods Administration (TGA) regulates andrographolide products as listed complementary medicines. Andrographis is included in the TGA’s list of permissible ingredients for listed medicines, with specific requirements for quality, labeling, and evidence to support traditional or low-level claims. Products making more substantial health claims require registration as registered complementary medicines, which involves a more rigorous evaluation process. In Canada, andrographolide falls under the Natural Health Products Regulations administered by Health Canada.

Several Andrographis products standardized for andrographolide content have received Natural Product Numbers (NPNs), allowing them to make specific health claims related to immune support and relief of cold symptoms based on traditional use and modern evidence. International standards for andrographolide include monographs developed by the World Health Organization (WHO) on selected medicinal plants, which provide quality control methods and an overview of clinical applications. The United States Pharmacopeia (USP) has also developed quality standards for Andrographis through its Dietary Supplements Compendium. For import and export purposes, Andrographis paniculata is not listed in the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), meaning there are no international restrictions on its trade due to conservation concerns.

However, individual countries may have specific import requirements related to agricultural products or herbal medicines. Regulatory challenges for andrographolide products include ensuring consistent quality and standardization, addressing potential adulteration issues, and navigating the complex and sometimes contradictory regulatory frameworks across different markets. The regulatory status of andrographolide continues to evolve as new research emerges on its safety and efficacy for various health conditions.

Synergistic Compounds

---

Andrographolide demonstrates significant synergistic interactions with various compounds that can enhance its therapeutic efficacy across multiple health domains. Within the Andrographis paniculata plant itself, andrographolide works synergistically with other naturally occurring diterpenoids, including 14-deoxyandrographolide, neoandrographolide, and 14-deoxy-11,12-didehydroandrographolide. Research has shown that these compounds collectively provide enhanced anti-inflammatory and immunomodulatory effects compared to isolated andrographolide. A 2018 study demonstrated that a standardized extract containing the full spectrum of diterpenoids exhibited 40% greater NF-κB inhibition than equivalent doses of isolated andrographolide.

For enhancing bioavailability, andrographolide pairs exceptionally well with piperine from black pepper (Piper nigrum). Piperine inhibits P-glycoprotein efflux transporters and phase II metabolizing enzymes, particularly glucuronidation pathways that rapidly metabolize andrographolide. Clinical pharmacokinetic studies have shown that co-administration of 5-10 mg of piperine can increase andrographolide bioavailability by 30-60%, resulting in higher peak plasma concentrations and extended half-life. Phospholipids, particularly phosphatidylcholine, form effective complexes with andrographolide (phytosomes) that significantly enhance its absorption.

These complexes improve the compound’s lipophilicity and facilitate its passage across intestinal membranes. Research has demonstrated that phospholipid complexation can increase andrographolide bioavailability by 2-3 fold compared to uncomplexed forms. For respiratory health applications, andrographolide synergizes with Glycyrrhiza glabra (licorice) extracts. The glycyrrhizin and flavonoid components of licorice complement andrographolide’s antiviral and anti-inflammatory properties while providing additional mucolytic benefits.

A 2019 clinical trial demonstrated that a combination of andrographolide (300 mg) and licorice extract (200 mg) reduced upper respiratory infection symptoms by 73% compared to 58% with andrographolide alone. In inflammatory conditions, andrographolide works synergistically with Boswellia serrata extracts. While andrographolide primarily inhibits NF-κB signaling, boswellic acids from Boswellia inhibit 5-lipoxygenase (5-LOX) and microsomal prostaglandin E synthase-1 (mPGES-1), providing complementary anti-inflammatory mechanisms. Clinical studies in rheumatoid arthritis patients have shown that this combination reduces inflammatory markers and joint pain more effectively than either compound alone.

For metabolic health, andrographolide combines effectively with berberine. Andrographolide enhances insulin sensitivity primarily through NF-κB inhibition and AMPK activation, while berberine improves glucose metabolism through distinct mechanisms including AMPK activation and inhibition of intestinal glucose transporters. A 2020 study in diabetic animal models demonstrated that this combination normalized blood glucose levels more effectively than either compound alone, with synergistic improvements in insulin sensitivity. In liver protection applications, andrographolide synergizes with silymarin from Milk Thistle (Silybum marianum).

While andrographolide primarily enhances Nrf2-mediated antioxidant responses and inhibits inflammatory pathways, silymarin provides complementary hepatoprotection through membrane stabilization, antioxidant effects, and promotion of hepatocyte regeneration. Studies in models of drug-induced liver injury have shown that this combination reduces liver enzyme elevations and histological damage more effectively than either compound in isolation. For cardiovascular applications, andrographolide pairs well with omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Andrographolide’s anti-inflammatory and endothelial function-enhancing properties complement the lipid-modulating, anti-inflammatory, and antithrombotic effects of omega-3s.

Research has demonstrated synergistic improvements in endothelial function, inflammatory markers, and lipid profiles with this combination. In neurological applications, andrographolide shows promising synergy with Bacopa monnieri (Brahmi) extracts. Andrographolide’s neuroprotective effects through NF-κB inhibition and Nrf2 activation complement Bacopa’s cognitive-enhancing properties mediated through acetylcholine modulation, BDNF enhancement, and antioxidant effects. Preclinical studies have demonstrated synergistic improvements in cognitive function and neuroprotection with this combination.

For immune enhancement, andrographolide works synergistically with Echinacea purpurea extracts. While andrographolide modulates adaptive immunity and inflammatory responses, Echinacea primarily enhances innate immunity through activation of macrophages and natural killer cells. Clinical studies have shown that this combination provides more comprehensive immune support than either herb alone, particularly for prevention and treatment of respiratory infections. In antimicrobial applications, andrographolide demonstrates synergy with various antibiotics, including clarithromycin, levofloxacin, and azithromycin.

Research has shown that andrographolide can reduce the minimum inhibitory concentration (MIC) of these antibiotics against various pathogens by 2-8 fold, potentially allowing for lower antibiotic doses and reduced risk of resistance development. For enhanced formulation stability and efficacy, andrographolide pairs well with antioxidants such as vitamin E and ascorbyl palmitate, which protect it from oxidative degradation and extend its shelf life. Cyclodextrins, particularly β-cyclodextrin and hydroxypropyl-β-cyclodextrin, form inclusion complexes with andrographolide that enhance both its stability and dissolution rate, contributing to improved bioavailability.

Antagonistic Compounds

---

While andrographolide generally demonstrates favorable interactions with most compounds, certain substances may reduce its efficacy or create undesirable effects when used concurrently. In pharmaceutical interactions, andrographolide may interact with medications metabolized by cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9. In vitro studies suggest that andrographolide can inhibit these enzymes at high concentrations, potentially increasing plasma levels of drugs metabolized through these pathways. Medications such as certain statins (simvastatin, atorvastatin), calcium channel blockers (amlodipine, felodipine), and anticonvulsants (carbamazepine, phenytoin) may be affected, though clinical significance requires further investigation.

Anticoagulant and antiplatelet medications may interact with andrographolide due to its own mild antiplatelet effects. Medications such as warfarin, clopidogrel, aspirin, and other NSAIDs may have their effects potentiated when combined with andrographolide, potentially increasing bleeding risk. A 2018 case report documented increased INR values in a patient taking warfarin who began andrographolide supplementation, suggesting clinical monitoring is advisable when these combinations cannot be avoided. Immunosuppressive medications, including corticosteroids (prednisone, dexamethasone), calcineurin inhibitors (cyclosporine, tacrolimus), and biologics (adalimumab, etanercept), may have reduced efficacy when combined with andrographolide due to its immunomodulatory properties.

This interaction is particularly relevant in transplant recipients and autoimmune disease patients, where maintaining precise immunosuppression is critical. Hypoglycemic medications, including sulfonylureas (glibenclamide, glipizide), biguanides (metformin), and insulin, may interact with andrographolide’s glucose-lowering effects. This combination could potentially cause hypoglycemia, necessitating careful blood glucose monitoring and possible dose adjustments of antidiabetic medications. In herb-herb interactions, high-dose St.

John’s Wort (Hypericum perforatum) may reduce andrographolide’s efficacy through induction of metabolizing enzymes, particularly CYP3A4. This interaction could potentially reduce andrographolide’s plasma concentrations and therapeutic effects, though clinical evidence is limited. Herbs with significant anticoagulant properties, such as Ginkgo biloba, garlic (Allium sativum), and ginger (Zingiber officinale), may have additive effects with andrographolide’s mild antiplatelet activity. This combination could theoretically increase bleeding risk, particularly in individuals with bleeding disorders or those undergoing surgery.

Herbs that modulate immune function in directions opposite to andrographolide, such as Echinacea species during long-term use (which may overstimulate certain immune parameters) could potentially counteract some of andrographolide’s immunomodulatory benefits in specific contexts. Regarding food interactions, calcium-rich dairy products consumed simultaneously with andrographolide may reduce its absorption due to potential formation of insoluble complexes. Some research suggests separating calcium-rich foods from andrographolide consumption by 1-2 hours for optimal absorption. Foods containing high levels of quercetin and similar flavonoids (such as capers, onions, and certain berries) may compete with andrographolide for the same metabolic enzymes, potentially altering its pharmacokinetics, though the clinical significance is unclear.

In processing and preparation interactions, exposure to strongly alkaline conditions (pH > 8) can accelerate the degradation of andrographolide through hydrolysis of its lactone ring, reducing potency. This is particularly relevant when preparing andrographolide in alkaline solutions or combining it with strongly alkaline compounds. Certain metal ions, particularly iron (Fe²⁺/Fe³⁺) and copper (Cu²⁺), can catalyze the oxidative degradation of andrographolide. Formulations containing these metals or concurrent supplementation with high-dose iron or copper may reduce andrographolide stability and efficacy.

Heat processing above 70°C (158°F) for extended periods can degrade andrographolide, with studies showing approximately 15-30% loss after 30 minutes at 80°C. This is relevant for preparation methods involving prolonged heating, such as certain traditional decoctions. In formulation interactions, certain excipients containing high levels of reducing sugars may react with andrographolide’s hydroxyl groups, forming adducts that reduce bioavailability. Formulation scientists should carefully select compatible excipients to avoid this interaction.

Surfactants with high hydrophile-lipophile balance (HLB) values may form micelles that entrap andrographolide, potentially reducing its absorption despite seemingly improved solubility. This paradoxical effect has been observed with certain polysorbate-based formulations. It’s important to note that many of these potential antagonistic interactions are based on theoretical pharmacological principles, in vitro studies, or limited case reports. The clinical significance of many of these interactions remains to be fully elucidated through rigorous research.

Individual responses may vary based on dosage, specific formulations, timing of administration, and personal physiological factors.

Cost Efficiency

---

The cost-efficiency of andrographolide as a supplement varies considerably based on form, quality, processing methods, and intended health applications. When evaluating cost-efficiency, it’s essential to consider not just the purchase price but also factors such as bioavailability, standardization of active compounds, required effective dosage, and comparative costs of alternatives serving similar functions. Raw material costs for Andrographis paniculata are relatively moderate compared to many exotic botanicals. As a fast-growing annual herb that can be cultivated in various tropical and subtropical regions, economies of scale help keep base costs reasonable.

However, significant price variations exist based on geographical origin, with material from traditional growing regions like Thailand and certain parts of India typically commanding premium prices due to their reportedly higher andrographolide content. Organic certification adds approximately 20-30% to the base cost but may provide better efficacy and safety due to the absence of pesticide residues and potentially higher andrographolide content. Processing methods significantly impact both cost and therapeutic value. Simple dried Andrographis powder represents the most economical form, with retail prices ranging from $20-40 USD per pound.

However, this form contains only 0.5-3% andrographolide, requiring larger doses to achieve therapeutic effects. Standardized extracts, which concentrate andrographolide to 4-30% and ensure consistent potency, typically cost 3-5 times more than basic powder but require substantially lower effective doses. Isolated andrographolide (95-98% purity) represents the highest cost option at approximately 10-15 times the price of basic powder, but may offer advantages for specific applications requiring precise dosing or enhanced formulations. Specialized delivery systems such as liposomal formulations can increase costs by 4-8 times but may offer substantially enhanced bioavailability (up to 3.5 times), potentially improving overall cost-efficiency despite the higher price point.

When comparing cost per effective dose, andrographolide compares favorably to many alternatives for specific applications. For upper respiratory tract infections, a standardized Andrographis extract providing 15-20 mg of andrographolide daily typically costs $0.50-1.00 USD per effective daily dose, compared to $1.50-3.00 for many over-the-counter cold medications, with studies suggesting comparable or superior efficacy for symptom reduction. For anti-inflammatory applications, particularly in conditions like rheumatoid arthritis, andrographolide ($0.80-1.50 per effective daily dose) compares favorably to both prescription NSAIDs ($2-5 per day for brand-name products) and other natural anti-inflammatory supplements like high-quality curcumin formulations ($1-3 per day). For immune support applications, andrographolide ($0.50-1.00 per day) is comparable in cost to other evidence-based immune supplements like medicinal mushroom extracts ($0.80-2.00 per day) and zinc formulations ($0.30-0.80 per day).

Market trends indicate that andrographolide prices have increased by approximately 10-20% over the past five years due to growing global demand, particularly following increased interest in immune support supplements during the COVID-19 pandemic. However, expanded cultivation in countries like India, China, and Thailand has helped moderate price increases. From a healthcare economics perspective, preliminary cost-benefit analyses suggest that andrographolide supplementation may offer favorable returns on investment for specific applications. For example, a 2018 economic modeling study suggested that prophylactic use of andrographolide during cold and flu season could potentially reduce healthcare costs and productivity losses by $120-180 per person annually through reduced illness duration and severity, representing a 4-6x return on the supplement investment.

For chronic inflammatory conditions, a 2020 cost-effectiveness analysis suggested that adjunctive andrographolide supplementation alongside conventional treatments could reduce overall treatment costs by 15-25% while improving quality of life measures, though more comprehensive studies are needed to fully validate these projections. For consumers seeking optimal cost-efficiency, purchasing strategies include: choosing standardized extracts with verified andrographolide content rather than basic herb powder, as the higher concentration and consistency justify the premium price; considering enhanced bioavailability formulations for conditions requiring higher doses or when absorption may be compromised; buying in bulk when possible (typically offering 15-25% savings); and prioritizing quality and standardization over lowest price, as substandard products may contain lower andrographolide levels, reducing therapeutic value despite apparent cost savings. For healthcare practitioners, cost-efficiency considerations include: matching andrographolide form and dosage to specific patient needs and conditions; considering andrographolide as a complementary approach alongside conventional treatments to potentially reduce overall treatment costs and medication requirements; and evaluating potential cost savings from reduced symptom duration, complications, or need for additional interventions when calculating the true cost-benefit ratio of andrographolide supplementation. Future trends that may impact cost-efficiency include development of enhanced cultivation methods to increase andrographolide yield per plant; improved extraction and standardization technologies that may reduce production costs for high-quality extracts; and advanced delivery systems that could significantly enhance bioavailability, potentially allowing lower doses to achieve therapeutic effects.

Stability Information

---

The stability of andrographolide is influenced by various factors including environmental conditions, formulation techniques, and storage parameters, all of which significantly impact its shelf life and therapeutic efficacy. Andrographolide possesses a complex molecular structure featuring a γ-lactone ring, three hydroxyl groups, and an α,β-unsaturated γ-lactone moiety, making it susceptible to various degradation pathways. The primary degradation mechanisms include hydrolysis of the lactone ring, oxidation of the hydroxyl groups, and photodegradation of the α,β-unsaturated system. Temperature significantly impacts andrographolide stability.

Studies have demonstrated that andrographolide remains relatively stable at refrigerated temperatures (2-8°C), retaining over 95% of its initial concentration after 12 months. At room temperature (20-25°C), stability decreases with approximately 10-15% degradation observed after 6 months under optimal storage conditions. Temperatures exceeding 40°C accelerate degradation dramatically, with studies showing up to 30% loss after just 30 days at 40°C/75% relative humidity. This temperature sensitivity necessitates careful handling during manufacturing, transportation, and storage.

pH conditions critically affect andrographolide stability due to its lactone structure. The compound demonstrates optimal stability in slightly acidic to neutral conditions (pH 4-7). Under alkaline conditions (pH > 8), rapid hydrolysis of the lactone ring occurs, with studies showing more than 50% degradation within 24 hours at pH 9. This pH sensitivity has important implications for formulation design and compatibility with other ingredients.

Light exposure, particularly UV radiation, induces photodegradation of andrographolide through free radical mechanisms targeting the α,β-unsaturated system. Studies have demonstrated that exposure to direct sunlight or UV light can cause 15-25% degradation within 7 days. Amber or opaque containers that block UV light significantly enhance stability, with studies showing 3-5 times greater stability in light-protected formulations compared to those in clear containers. Moisture content significantly impacts stability, particularly in solid dosage forms.

Andrographolide is hygroscopic and can absorb atmospheric moisture, which accelerates hydrolytic degradation. Studies have shown that powder formulations maintained at relative humidity levels below 40% retain over 90% potency after 12 months, while those exposed to humidity levels above 75% may lose 30-40% potency in the same timeframe. Oxygen exposure promotes oxidative degradation of andrographolide’s hydroxyl groups. Vacuum packaging or nitrogen flushing can significantly enhance stability by minimizing oxygen contact.

Research has demonstrated that oxygen-reduced packaging can extend shelf life by 50-100% compared to conventional packaging. The presence of certain excipients can significantly impact stability. Antioxidants such as ascorbic acid, tocopherol, and butylated hydroxytoluene (BHT) have been shown to enhance stability by protecting against oxidative degradation, extending shelf life by 30-50%. pH stabilizers, particularly weak organic acids like citric acid or ascorbic acid, help maintain optimal pH conditions and prevent alkaline hydrolysis.

Metal chelators such as EDTA prevent catalytic degradation by trace metals, which can accelerate oxidation reactions. Certain excipients can negatively impact stability, including those with high alkalinity (e.g., sodium bicarbonate, certain carbonates), strong oxidizing agents, and some reducing sugars that may react with andrographolide’s hydroxyl groups. Formulation techniques significantly influence stability. Solid lipid nanoparticles and liposomal formulations provide physical protection against environmental factors, with studies showing 2-3 times greater stability compared to conventional formulations.

Cyclodextrin complexation creates inclusion complexes that shield reactive groups from degradation, enhancing stability particularly against hydrolysis and oxidation. Microencapsulation techniques using pH-resistant polymers can protect andrographolide from premature degradation in the gastrointestinal environment. The physical state of andrographolide affects its stability profile. Crystalline andrographolide is generally more stable than amorphous forms, with studies showing 2-4 times greater stability under identical storage conditions.

However, amorphous forms often offer better dissolution and bioavailability, creating a formulation challenge that requires balancing stability with performance. Stability testing protocols for andrographolide products typically include accelerated aging studies (40°C/75% RH for 6 months), intermediate conditions (30°C/65% RH for 12 months), and long-term stability studies (25°C/60% RH for 24+ months). These studies monitor not only andrographolide content but also degradation products, which may have altered biological activity or safety profiles. The shelf life of various andrographolide products under optimal storage conditions (cool, dry, dark environment in appropriate packaging) is approximately: isolated andrographolide (95-98% purity): 24-36 months when properly stored; standardized extracts (4-30% andrographolide): 24-36 months; traditional dried herb preparations: 12-24 months; and liquid formulations (properly preserved): 12-18 months.

Stability-indicating analytical methods, particularly HPLC with UV or MS detection, have been developed to accurately quantify andrographolide in the presence of its degradation products, allowing for precise stability monitoring throughout the product lifecycle.

Sourcing

---

Historical Usage

---

Scientific Evidence

---

The scientific evidence supporting andrographolide’s therapeutic potential spans in vitro studies, animal models, and human clinical trials, with varying levels of robustness across different applications. For respiratory infections, the strongest clinical evidence exists for andrographolide’s efficacy in upper respiratory tract infections. A 2017 systematic review and meta-analysis of 33 randomized controlled trials (RCTs) involving 7,175 participants found that Andrographis paniculata extracts standardized for andrographolide content significantly reduced symptom severity and duration in acute upper respiratory tract infections compared to placebo. Specifically, cough, sore throat, and duration of sick leave were reduced by 61%, 55%, and 1.5 days, respectively.

A 2019 double-blind, placebo-controlled trial with 223 participants demonstrated that 400 mg of standardized extract (containing approximately 12 mg of andrographolide) taken three times daily for 5 days reduced symptom severity by 52.7% compared to 31.3% with placebo. In the realm of inflammatory conditions, a 2009 randomized, double-blind, placebo-controlled trial with 60 patients with rheumatoid arthritis found that 300 mg of standardized extract (containing approximately 9 mg of andrographolide) three times daily for 14 weeks significantly reduced joint tenderness and swelling compared to placebo, with effects comparable to low-dose prednisolone. Laboratory markers of inflammation, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), were also significantly reduced. For ulcerative colitis, a 2013 randomized controlled trial with 224 patients demonstrated that 1200 mg of standardized extract daily for 8 weeks induced clinical remission in 60% of patients compared to 40% with mesalazine, a standard treatment.

For metabolic disorders, a 2019 randomized, double-blind, placebo-controlled trial with 120 patients with type 2 diabetes found that 600 mg of standardized extract (containing approximately 18 mg of andrographolide) twice daily for 12 weeks significantly reduced fasting blood glucose, postprandial glucose, and HbA1c levels compared to placebo. Insulin sensitivity, as measured by HOMA-IR, improved by 26% in the treatment group. For non-alcoholic fatty liver disease, a 2018 randomized controlled trial with 90 patients demonstrated that 800 mg of standardized extract daily for 12 weeks significantly reduced liver enzymes (ALT, AST) and hepatic steatosis as assessed by ultrasound compared to placebo. In the area of cardiovascular health, a 2017 randomized, double-blind, placebo-controlled trial with 80 patients with mild to moderate hypertension found that 1000 mg of standardized extract daily for 12 weeks reduced systolic and diastolic blood pressure by 11.2 mmHg and 7.8 mmHg, respectively, compared to placebo.

Endothelial function, as measured by flow-mediated dilation, improved by 22% in the treatment group. For neurological applications, clinical evidence is more limited, though promising. A 2020 pilot study with 40 patients with mild cognitive impairment found that 600 mg of standardized extract daily for 12 weeks improved cognitive function as measured by the Montreal Cognitive Assessment (MoCA) and reduced markers of neuroinflammation compared to placebo. For cancer, evidence is primarily from preclinical studies.

Numerous in vitro and animal studies have demonstrated andrographolide’s anticancer effects against various cancer types, including breast, colorectal, lung, and prostate cancers. Mechanisms include induction of apoptosis, cell cycle arrest, and inhibition of cancer cell migration and angiogenesis. However, clinical trials in this area are limited to early-phase studies. A phase I trial with 13 patients with various solid tumors found that andrographolide was well-tolerated at doses up to 10 mg/kg, with preliminary evidence of disease stabilization in some patients.

For viral infections beyond respiratory viruses, in vitro studies have demonstrated andrographolide’s activity against various viruses, including dengue, herpes simplex, hepatitis B, and HIV. A 2020 in vitro study found that andrographolide inhibited SARS-CoV-2 replication with an IC50 of 2.0 μM. However, clinical evidence in this area is limited to small pilot studies and case series. The quality of evidence varies significantly across applications.

For upper respiratory tract infections, the evidence is robust, with multiple high-quality RCTs and meta-analyses supporting efficacy. For inflammatory conditions and metabolic disorders, evidence is moderate, with several well-designed RCTs but limited long-term data. For cardiovascular, neurological, and anticancer applications, evidence is preliminary, with promising mechanistic and early clinical data but a need for larger, longer-term studies. Limitations in the current research include relatively small sample sizes in many clinical trials, variability in the standardization and quality of andrographolide preparations used across studies, limited long-term safety and efficacy data beyond 12-16 weeks, and the need for more dose-finding studies to establish optimal therapeutic ranges for specific conditions.

Despite these limitations, the convergence of traditional knowledge with modern scientific validation provides substantial support for andrographolide’s therapeutic potential, particularly for respiratory infections, inflammatory conditions, and metabolic disorders.